Big biologics bet: China's Innovent gets $100m financing
This article was originally published in Scrip
Executive Summary
A record-breaking private financing for a Chinese biotech has seen bets placed on Suzhou-based Innovent Biologics, which has 10 monoclonal antibodies including four biosimilars in its pipeline.